In our previous prospective studies, the incidences of DT and hypothyroidism were 6.7 and 3.1% during PD-1-Ab therapy [9] and 5.4 and 4.7% during PD-L1-Ab therapy [10], respectively. This evidence concerns the gene CD274 and hypothyroidism.